For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

This could start to bring down the cost of brand-name competitors—here's who may get to use it, and one major difference from ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...

Not long after the FDA wrapped its preliminary investigation of GLP-1 receptor agonists and suicidal thoughts or actions, the ...

FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes ...

The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...

The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), ...

GLP-1 receptor agonists, such as liraglutide, semaglutide, and exenatide, are designed to replicate the actions of the glucagon-like peptide-1 hormone, which naturally regulates blood sugar and ...